[L'OMS a mis à jour ses listes d'ARV et d'antituberculeux préqualifiés sur son site http://www.who.int/prequal/ Remerciements pour l'info à Marie-Louise Ngoko.CB]
Prequalification Update - 20 December 2007
1. WHO Prequalification Programme adds 4 new WHO Public Assessment Reports
(WHOPARs)
The WHOPARs (marked in red in WHOPAR table) cover the following products:
* HA303: Lamivudine/Stavudine 150mg/30mg tablets (Cipla Limited)
* HA304: Lamivudine/Stavudine 150mg/40mg tablets (Cipla Limited)
* TB157: Ethambutol/Isoniazid 400mg/150mg tablets (Macleods Pharmaceuticals
Ltd)
* TB159: Pyrazinamide 400mg tablets (Macleods Pharmaceuticals Ltd)
Related Link: Overview of WHOPARs of Prequalified Medicinal Products
2. WHO Prequalification Programme adds new manufacturing sites to its list
of prequalified HIV products
Manufacturing sites have been added to the HIV/AIDS List for products:
* HA108: Zidovudine 100mg capsules GlaxoSmithKline
* HA109: Zidovudine 250mg capsules GlaxoSmithKline
New site for HA108 and HA109: Crawley, West Sussex, UK
* HA329: Tenofovir disoproxil fumarate 300mg tablets Gilead Sciences,
Inc.
* HA343: Emtricitabine/Tenofovir disoproxil fumarate 200mg/300mg tablets
Gilead Sciences, Inc.
Additional site for HA329 and HA343: Aspen Pharmacare, OSD Facility,
Korsten, Port Elizabeth, South Africa
Related Link: 61st Edition List of HIV/AIDS Prequalified Products and
Manufacturers